{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001690","form_type":"8-K","ticker":"BBNX","cik":"0001674632","company_name":"Beta Bionics, Inc.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.400746+00:00","generated_at":"2026-05-24T05:50:38.434365+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Beta Bionics Q4 revenue up 145% to $20.4M; FY2025 guidance $80-85M","bullets":["Q4 net sales $20.4M (+145% YoY); FY2024 net sales $65.1M (+443% YoY). Installed base 15,298 users (+564%).","Operating loss Q4 $13.0M (neg 64% of sales); net loss $18.1M. Full year operating loss $45.3M.","Cash $103.6M at Dec 31, 2024; raised ~$206M net from IPO/private placement in Jan 2025.","FY2025 guidance: revenue $80-85M, >20% new patient starts from PBP channel, gross margin ≥50%.","Prime Therapeutics added iLet to national commercial formulary; first-to-market integration with Abbott FreeStyle Libre 3 Plus."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001690","json":"https://secwatch.observer/filing/0001171843-25-001690.json","markdown":"https://secwatch.observer/filing/0001171843-25-001690.md","text":"https://secwatch.observer/filing/0001171843-25-001690.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674632/000117184325001690/0001171843-25-001690-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674632/000117184325001690/f8k_032525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:50:38.434365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}